Does atherosclerosis caused by dialysis limit this treatment?

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Epidemiology

Background:

• Cardiovascular and cerebrovascular diseases are major concerns for patients undergoing dialysis.
• Atherosclerosis-related mortality in dialysis patients requires further investigation regarding its association with treatment duration.

Purpose of the Study:

• To investigate the relationship between the duration of dialysis treatment and the rates of cardiovascular and cerebrovascular death.
• To identify key pre-dialysis factors influencing cardiovascular and cerebrovascular morbidity and mortality in dialysis patients.

Main Methods:

• Retrospective study analyzing data from 332 dialysis patients.
• Observation period extended up to 17 years.
• Data analysis focused on cardiovascular and cerebrovascular events and mortality in relation to dialysis duration and pre-dialysis health status.

Main Results:

• No increase in cardiovascular and cerebrovascular death rates due to atherosclerosis was observed with longer dialysis treatment duration.
• High blood pressure predating dialysis initiation was a primary cause of cardiovascular and cerebrovascular morbidity and mortality.
• An unfavorable very low-density lipoprotein/high-density lipoprotein (VLDL/HDL) cholesterol quotient at the start of dialysis was also a significant contributing factor.

Conclusions:

• The length of time on dialysis does not appear to elevate the risk of atherosclerosis-related cardiovascular and cerebrovascular death.
• Patient management and health status, particularly blood pressure and cholesterol levels, prior to commencing dialysis are critical determinants of long-term prognosis.